Many investors are closely watching Bio Medica Laboratories Limited because the company operates in the growing pharmaceutical manufacturing sector with a strong B2B business model.
About Bio-Medica Laboratories Business
Bio Medica Laboratories Limited is a pharmaceutical company that mainly manufactures pharmaceutical formulations, generic injections, and liquid injections for both human and veterinary use. The company offers a wide range of healthcare products in single-dose, double-dose, and multiple-dose formats. The company primarily operates on a B2B model, generating revenue through contract manufacturing for pharmaceutical companies in India and international markets. Along with manufacturing, the company also supplies its products globally to healthcare-related industries.
Bio Medica Laboratories also has its own research and development (R&D) center and strongly focuses on GMP (Good Manufacturing Practices) and GLP standards to maintain high product quality and safety standards. In addition, the company exports pharmaceutical products to foreign countries and healthcare markets outside India.
Bio Medica Laboratories IPO Price & Investment Details
| IPO Details | Information |
|---|---|
| Company Name | Bio Medica Laboratories Limited |
| IPO Type | SME IPO |
| Exchange | NSE SME |
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Allotment Date | 26 May 2026 |
| Listing Date | 29 May 2026 |
| Price Band | ₹132 – ₹139 per share |
| Face Value | ₹10 per share |
| Lot Size | 1,000 Shares |
| Minimum Investment | ₹1,39,000 – ₹2,78,000 |
| Total Issue Size | ₹52.43 Crore |
| Fresh Issue | ₹47.19 Crore |
| Offer for Sale (OFS) | ₹5.24 Crore |
| Registrar | Skyline Financial Services Pvt. Ltd. |
| Lead Manager | Narnolia Financial Services Ltd. |
| Business Type | Pharmaceutical Contract Manufacturing |
| Product Segment | Liquid Injections & Dry Powder Injections |
| Healthcare Segment | Human & Veterinary |
| Business Model | B2B Contract Manufacturing |
| Listing Platform | NSE, SME |
Bio Medica Laboratories Financial Report
| Financials (₹ Crore) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 16.22 | 15.24 | 38.19 |
| EBITDA | 1.71 | 5.72 | 15.33 |
| Profit After Tax (PAT) | 0.33 | 2.49 | 9.79 |
| Total Assets | 17.56 | 19.53 | 39.11 |
| Net Worth | 4.94 | 8.03 | 7.39 |
| Total Debt | 9.60 | 9.98 | 15.00 |
| EBITDA Margin | 10.54% | 37.53% | 40.14% |
| PAT Margin | 2.03% | 16.34% | 25.63% |
| EPS (₹) | 0.36 | 2.72 | 10.67 |
| ROE (%) | 6.68% | 31.01% | 132.48% |
| ROCE (%) | 10.16% | 29.92% | 48.20% |
Bio Medica Laboratories IPO – Pros and Cons
| Pros | Cons |
|---|---|
| Strong revenue growth in FY25 | SME IPOs generally carry higher risk and volatility |
| Highly competitive pharmaceutical industry | Regulatory compliance risk in the pharma sector |
| Manufactures products for both human and veterinary healthcare | Rising debt levels in recent financial years |
| Focus on GMP and GLP quality standards | Smaller company compared to large pharma players |
| Global supply and export business presence | SME stocks may have lower liquidity after listing |
| Own research & development (R&D) center | Revenue concentration risk from limited clients |
| Wide range of injection and formulation products | The company operates in the pharmaceutical sector |
| B2B business model provides manufacturing opportunities | Businesses heavily depend on contract manufacturing |
| Highly competitive pharmaceutical industryThe | Future growth sustainability still needs monitoring |
| Increasing operational efficiency | great improvement in profitability and margins |
Bio Medica Laboratories Contact Details Office Address
Unit No.1
Plot No.254, Sector-F, Sanwer Road Industrial Area, Sanwer Road, Indore – 452 015 (MP)
Unit No.2
Registered Office: Plot No. 11B & 11C, Sector-E, Sanwer Road, Industrial Area, Indore – 452015 (MP)
Email: bmlpl2014@biomedica.co.in
Contact: +91 9827210008 / +91 7999274343
website: biomedica.co.in
Conclusion
Bio Medica Laboratories Limited operates in the pharmaceutical manufacturing sector with a B2B-focused business model. The company manufactures formulations, generic injections, and liquid injections for both human and veterinary healthcare segments while also supplying products globally. Its focus on GMP and GLP standards, contract manufacturing business, and strong financial growth in FY25 has attracted investor attention toward this IPO.
At the same time, investors should also understand that SME IPOs usually come with higher risk, lower liquidity, and business uncertainty compared to larger listed companies. Before applying for the IPO, investors should carefully analyze the company’s financials, debt levels, business sustainability, risks, and long-term growth potential according to their own risk tolerance and investment goals.
Disclaimer
This article is only for educational and informational purposes. We are not SEBI-registered financial advisors. Please do your own research before investing in any IPO or stock market product. The author, writer, and Namos are not responsible for any profit or loss in the stock market.
